Dr. S. Vincent Rajkumar on a New Bortezomib Triplet in Multiple Myeloma

S. Vincent Rajkumar, MD, professor of medicine, Mayo Clinic, discusses bortezomib, lenalidomide, and dexamethasone coming out on top in a recent phase III trial over lenalidomide and dexamethasone alone.

The findings of the phase III trial, labeled SWOG S0777, showed a 13-month improvement in progression-free survival and a 29% reduction of risk of death with the triplet of bortezomib, lenalidomide, and dexamethasone, compared with lenalidomide and dexamethasone alone. Findings from the study suggest the triplet should be a new standard of care for untreated patients with multiple myeloma. Rajkumar said the triplet is now the new standard of care at the Mayo Clinic for multiple myeloma.